Trial Profile
A study to evaluate the clinical and microbial efficacy and safety of 1.0% AzaSite compared to 0.3% tobramycin ophthalmic solution in the treatment of bacterial conjunctivitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Azithromycin (Primary) ; Tobramycin
- Indications Infectious conjunctivitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 26 Oct 2011 Actual end date (Oct 2005) added as reported by ClinicalTrials.gov.
- 30 Sep 2005 New trial record.